Research analysts at Needham & Company LLC assumed coverage on shares of ZimVie (NASDAQ:ZIMV – Get Free Report) in a research report issued on Thursday, MarketBeat Ratings reports. The brokerage set a “hold” rating on the stock.
A number of other research analysts have also recently commented on the company. JPMorgan Chase & Co. cut their target price on ZimVie from $15.00 to $10.00 and set a “neutral” rating on the stock in a research note on Thursday, November 2nd. Barclays upped their target price on ZimVie from $7.00 to $11.00 and gave the company an “underweight” rating in a research note on Monday, August 7th.
ZimVie Trading Up 5.2 %
Institutional Trading of ZimVie
A number of large investors have recently modified their holdings of the company. Keeley Teton Advisors LLC lifted its holdings in ZimVie by 22.6% during the first quarter. Keeley Teton Advisors LLC now owns 95,217 shares of the company’s stock worth $688,000 after buying an additional 17,532 shares during the period. Factorial Partners LLC lifted its holdings in ZimVie by 173.8% during the first quarter. Factorial Partners LLC now owns 142,400 shares of the company’s stock worth $1,030,000 after buying an additional 90,400 shares during the period. Los Angeles Capital Management LLC purchased a new stake in ZimVie during the second quarter worth $334,000. Acadian Asset Management LLC lifted its holdings in ZimVie by 682.5% during the second quarter. Acadian Asset Management LLC now owns 673,277 shares of the company’s stock worth $7,556,000 after buying an additional 587,233 shares during the period. Finally, Strs Ohio lifted its holdings in ZimVie by 203.7% during the first quarter. Strs Ohio now owns 89,900 shares of the company’s stock worth $649,000 after buying an additional 60,300 shares during the period. Hedge funds and other institutional investors own 85.16% of the company’s stock.
ZimVie Company Profile
ZimVie Inc, a medical technology company, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; hardware and software solutions consist of intraoral scanners and RealGUIDE; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
- Five stocks we like better than ZimVie
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 large caps with red hot RSIs with upside
- How to Start Investing in Penny Stocks
- Johnson Controls International: Nothing but upside for investors
- Transportation Stocks Investing
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.